ArticleAntibiotics (Basel, Switzerland)2024
Evolution of Antimicrobial Resistance in
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of multidrug-resistantFrontiers in microbiology · 2025Pooled it
- Phage anti-defense genes targeting NADVirulence · 2026Article
- Antimicrobial Resistance and Stewardship in Surgical Departments: A Three-Year Single-Center Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Biofilm-Forming Capacity andAntibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.BMC infectious diseases · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Prevalence and molecular characterization of ESBL-producing Enterobacterales in clinical samples from the Boucle du Mouhoun region in Burkina Faso.BMC infectious diseases · 2026Article
- Temporal Trends in Antibiotic Resistance of Klebsiella pneumoniae and Antibiotic Consumption: A Six-year Longitudinal Surveillance Study : Temporal Trends of Resistance and Consumption of Antibiotics to K. pneumoniae.Journal of epidemiology and global health · 2026Article
- A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs.PNAS nexus · 2026Article
- Genomic and Clinical Profile of HypervirulentPathogens (Basel, Switzerland) · 2026Article
- Epidemiology of Urinary Pathogens and Antibiotic Resistance Trends: A Retrospective Analysis Stratified by Age and Sex from a Large Tertiary Hospital in Saudi Arabia.Infection and drug resistance · 2026Article
- Hospital-Based Genomic Surveillance ofBiology · 2025Article
- The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Resistance Trends, Resistance Mechanisms, and Antibiotic Consumption in COVID-19 Versus Non-COVID-19 Units: A Seven-Year Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2025Article
- Characteristics of Klebsiella pneumoniae and carbapenem-resistant Klebsiella pneumoniae clinical isolates from COVID-19 patients: a single-center retrospective analysis in a tertiary hospital, China.BMC infectious diseases · 2025Article
- Article
- One-year surveillance of last-resort antimicrobial resistance patterns in carbapenemase-producingGerms · 2025Article
- Evaluation of the impact of synthesized carbon nanoparticles on extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: investigating antibacterial and cytotoxic properties.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Multidrug-resistantmSystems · 2025Article
- Incidence, clinical and genomic trends of hospital- and Non-hospital-onset KPC-producing Klebsiella pneumoniae infections before and during the COVID-19 era: a ten-year interrupted time series study.Antimicrobial resistance and infection control · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe antimicrobial resistance (AMR) of
methodsWe conducted a retrospective study on
resultsThe rates of AMR increased for third-generation cephalosporins, carbapenems, aminoglycosides, fluoroquinolones, and colistin and decreased for trimethoprim/sulfamethoxazole (TMP/SMX), 45.7% in 2019 vs. 28.3% in 2021. A longer length of hospital stay (ꭓ
conclusionsThe AMR of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.